Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px
Organisation › Details

Noxxon (Group)

NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, a chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer® therapeutics: > NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) and is currently completing a Phase Ib study in healthy subjects and diabetics as well as a renal impairment study. A Phase II study in diabetics with renal impairment is planned to begin in April 2012. > NOX-A12 targets SDF-1 (CXCL12), a chemokine mediator of tumor invasion, metastasis and resistance to chemotherapy, has completed Phase I. Phase IIa studies in two hematological cancers, multiple myeloma and chronic lymphocytic leukemia will begin in April 2012. > NOX-H94 targets hepcidin, the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease, and is currently in a comprehensive single and multiple ascending dose Phase I study. An endotoxin challenge study, designed to test the ability of NOX-H94 to block hepcidin mediated hypoferremia is currently running and a Phase II of NOX-H94 in myeloma or lymphoma patients with anemia is planned to start mid-2012. The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team. *


Period Start 1997-01-01 established
Products Industry drug development technology
  Industry 2 Spiegelmer® technology
Persons Person Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev)
  Person 2 Buchanan, Iain (Noxxon 201009– interim CEO before Novexel CEO before Vertex Pharmaceuticals)
Region Region Berlin
  Country Germany
  Street 8–10 Max-Dohrn-Str.
  City 10589 Berlin
  Tel +49-30-726247-0
    Address record changed: 2017-10-01
Basic data Employees C: 51 to 100 (2011-09-06)
  Currency EUR
  Annual sales 83,000 (revenues (2016) 2016-12-31)
  Profit -10,752,000 (2016-12-31)
  Cash 2,214,000 (2016-12-31)
    * Document for �About Section�: 
Record changed: 2018-04-15


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Noxxon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

» top